Bharat Immunologicals & Biologics Ltd (BSE: 524663) is a Bulandshahr, Uttar Pradesh-based company in the Vaccines and Biologics industry. With a market capitalisation of ₹43 Cr, it ranks #3,990 by market cap among the 6,137 Indian listed companies on FinBizNet, and #2 of 2 in Vaccines and Biologics. At ₹9.55 (as of 25 Oct 2026), the share price is 56.9% below its 52-week high of ₹22.18 and -33.0% above its 52-week low of ₹14.25. The share price is down 29.7% over one year and down 11.0% over three months.
| Current Price | ₹9.55 |
|---|---|
| Market Cap | ₹43 Cr |
| BSE Code | 524663 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Vaccines and Biologics |
| P/E Ratio | -2.5 |
| Return on Equity | -17.19% |
| Return on Assets | -5.00% |
| 52-Week Range | ₹14.25 – ₹22.18 |
| 1-Year Price Change | -29.7% |
| 3-Month Price Change | -11.0% |
| Beta (1Y) | 0.39 |
| Headquarters | Bulandshahr, Uttar Pradesh |
| Website | bibcol.sciencecentral.in |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-5 Cr |
| EPS (Basic) | ₹-1.08 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.
1. Oral Polio Vaccine-This segment manufactures oral polio vaccine. 2. BIBSANIT-0 3. Segment Adjustment-0 4. BIB Sweet Tablets-This segment manufactures sweet tablets.
1. Oral Polio Vaccine-100% 2. BIBSANIT-0%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Panacea Biotec Ltd. | ₹2,203 Cr | -397.6 | -0.86% | ₹200 Cr | -30.9% |
| Bharat Immunologicals & Biologics Ltd | ₹43 Cr | -2.5 | -17.19% | ₹0 Cr | -29.7% |
Listed by market capitalisation. Ratios are shown for context only.
Bharat Immunologicals & Biologics Ltd is trading at ₹9.55, with a market capitalisation of ₹43 Cr.
Bharat Immunologicals & Biologics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Vaccines and Biologics).
Bharat Immunologicals & Biologics Ltd has a P/E of -2.5 and a return on equity of -17.19%.
Bharat Immunologicals & Biologics Ltd is listed on the BSE under the scrip code 524663.
Bharat Immunologicals & Biologics Ltd's share price is down 29.7% over one year and down 11.0% over three months. Its 52-week range is ₹14.25 to ₹22.18.
In Q3 FY23, Bharat Immunologicals & Biologics Ltd reported revenue of ₹0 Cr and net profit of ₹-5 Cr, with basic EPS of ₹-1.08 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.